title: The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?
abstract: The National Lipid Association (NLA) recently released recommendations for the treatment of dyslipidemias. These recommendations have commonalities and differences with those of other major societies with respect to risk assessment, lifestyle therapy, targets of therapy, and the use of non-statin agents. In this review, we compare the basic elements of the guidelines from each major society to provide clinicians with a comprehensive document reviewing the key principles of each.
authors.affiliation: Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York University Medical Center, 530 First Avenue, Schwartz 4F, New York, NY, 10016, USA, Laura.Flink@nyumc.org.
authors.forename: Laura
authors.initials: L
authors.lastname: Flink
authors.forename: James A
authors.initials: JA
authors.lastname: Underberg
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Newman
authors.forename: Eugenia
authors.initials: E
authors.lastname: Gianos
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D019468:Disease Management; D050171:Dyslipidemias / Q000175:diagnosis / Q000628:therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D058607:Fibric Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D010347:Patient Care Planning; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D012955:Societies, Medical
chemical_list: D000924:Anticholesteremic Agents; D015525:Fatty Acids, Omega-3; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin